Literature DB >> 17569146

Effects of aqueous extracts of Aconitum carmichaeli, Rhizoma bolbostemmatis, Phytolacca acinosa, Panax notoginseng and Gekko swinhonis Gūenther on Bel-7402 cells.

Zhu-Chen Yan1, Dan Chen, Xiong-Zhi Wu, Guang-Ru Xie, Yi Ba, Zhao Yan.   

Abstract

AIM: To investigate the anticancer activity of a chinese medical mixture, WRCP (warming and relieving Cold Phlegm), on hepatocarcinoma Bel-7402 cells.
METHODS: Fingerprints of WRCP, which were composed of aqueous extracts of Aconitum carmichaeli, Rhizoma bolbostemmatis, Phytolacca acinosa, Panax notoginseng and Gekko swinhonis Guenther, and aconitine, which could be isolated from Aconitum carmichaeli and have the potential toxicity, were identified by high pressure liquid chromatography. Bel-7402 cells were grown in the presence of WRCP, As(2)O(3) or all-trans-retinoic acid (ATRA). Cell proliferation and viability were determined by trypan blue stain. Apoptosis and cell cycle of Bel-7402 cells were detected by flow cytometry. Morphologic and ultrastructural variations were determined under optic and electronic microscopy. The secretion of alpha-fetoprotein and albumin was detected by radioimmunoassay.
RESULTS: The average quality of aconitine is 1.15 +/- 0.10 microg per 7.5 g extracts. WRCP could suppress the proliferation and viability of Bel-7402 cells. The percentage of apoptosis cells and S phase cells increased on WRCP-treated cells. Treated with WRCP, Bel-7402 cells showed ultrastructural features of differentiation. The alpha-fetoprotein secretion decreased while the albumin secretion increased (P < 0.001, P < 0.001, respectively) markedly in WRCP-treated cells.
CONCLUSION: WRCP can affect the proliferation, differentiation and apoptosis of Bel-7402 cells. It can arrest cells in S phase and has strong cytotoxicity to Bel-7402 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569146      PMCID: PMC4147126          DOI: 10.3748/wjg.v13.i19.2743

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

Review 1.  Apoptosis in hepatocellular carcinoma.

Authors:  Jannis Kountouras; Christos Zavos; Dimitrios Chatzopoulos
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

2.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Effects of Gekko sulfated polysaccharide on the proliferation and differentiation of hepatic cancer cell line.

Authors:  XiongZhi Wu; Dan Chen; Guang-Ru Xie
Journal:  Cell Biol Int       Date:  2006-04-27       Impact factor: 3.612

4.  Cancer statistics, 1997.

Authors:  S L Parker; T Tong; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

Review 5.  Epidemiological characteristics and risk factors of hepatocellular carcinoma.

Authors:  C J Chen; M W Yu; Y F Liaw
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

Review 6.  Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives.

Authors:  M Okuno; S Kojima; H Moriwaki
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

Review 7.  Cell cycle regulators and human hepatocarcinogenesis.

Authors:  A M Hui; M Makuuchi; X Li
Journal:  Hepatogastroenterology       Date:  1998 Sep-Oct

Review 8.  The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma.

Authors:  S Sell
Journal:  Int J Dev Biol       Date:  1993-03       Impact factor: 2.203

Review 9.  [MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications].

Authors:  L Petraccia; P Onori; R Sferra; M C Lucchetta; G Liberati; M Grassi; E Gaudio
Journal:  Clin Ter       Date:  2003 Sep-Oct

Review 10.  Curative therapeutic approaches to APL.

Authors:  M S Tallmann
Journal:  Ann Hematol       Date:  2004       Impact factor: 3.673

View more
  8 in total

1.  Anticancer effects of 5-fluorouracil combined with warming and relieving cold phlegm formula on human breast cancer.

Authors:  Xue-Lin Wang; Feng Ma; Xiong-Zhi Wu
Journal:  Chin J Integr Med       Date:  2011-12-08       Impact factor: 1.978

2.  Induction of apoptosis and cell cycle arrest in human HCC MHCC97H cells with Chrysanthemum indicum extract.

Authors:  Zong-Fang Li; Zhi-Dong Wang; Yuan-Yuan Ji; Shu Zhang; Chen Huang; Jun Li; Xian-Ming Xia
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

3.  Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma.

Authors:  Ya-Nan Man; Xiao-Hui Liu; Xiong-Zhi Wu
Journal:  Chin J Integr Med       Date:  2014-12-24       Impact factor: 1.978

4.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

5.  A Novel Pharmacological Method to Study the Chinese Medicinal Formula Hua-Zheng-Hui-Sheng-Dan.

Authors:  Rui Cao; Hong Zhang; Jie Guo; Xiao-Hui Liu; Chang Liu; Cui-Hong Zhu; Xiong-Zhi Wu
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-01       Impact factor: 2.629

6.  Ruanjian Sanjie decoction exhibits antitumor activity by inducing cell apoptosis in breast cancer.

Authors:  Xiumei Zhao; Jing Zhao; Renjie Hu; Qiang Yao; Guixian Zhang; Hongsheng Shen; Ernesto Yagüe; Yunhui Hu
Journal:  Oncol Lett       Date:  2017-03-08       Impact factor: 2.967

7.  Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models.

Authors:  Jingxiao Wang; Xinjie Yang; Haibo Han; Limin Wang; Weiqian Bao; Shanshan Wang; Robert M Hoffman; Meng Yang; Hui Qi; Chao An; Kaiwen Hu
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

8.  The System Research of the Molecular Mechanism of Quyushengxin Capsule in the Treatment of Osteonecrosis of the Femoral Head.

Authors:  Xia Du; Lintao Zhao; Yuan Qiao; Yuan Liu; Dong Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-11       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.